BioVaxys Technology Corp. (BIOV)
CSE
Closed
Oct 5, 2026
Day's Range
0.070052 wk Range
0.0300Overview - BIOV - BioVaxys Technology Corp.
Key Statistics
Valuation
Enterprise Value
2.17M
P/E (Trailing)
‪-0.35‬
PEG Ratio
‪0.0035‬
Price / Book
‪-0.73‬
EV / EBITDA
‪-0.82‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-152.79%‬
Return on Equity
‪205.96%‬
Ownership
Shares Outstanding
29.15M
Float
26.13M
Held by Insiders
‪8.22%‬
Held by Institutions
‪0.00%‬
Price stats
Beta
‪1.08‬
50-Day Avg
‪0.0700‬
200-Day Avg
‪0.0997‬
Market Cap - BIOV - BioVaxys Technology Corp.
Peers - BIOV - BioVaxys Technology Corp.
Peer Comparison
Compared with companies in Biotechnology listed on CSE.
- BIOVCSEBioVaxys Technology Corp.2.84MMarket Cap-321.43%52-week change-0.35P/E (Trailing)‪0.00%‬Profit Margin
- BETRCSEBetterLife Pharma Inc.207.03MMarket Cap+77.61%52-week change-33.50P/E (Trailing)‪0.00%‬Profit Margin
- BLABCSEBritannia Life Sciences Inc.9.87MMarket Cap-58.33%52-week change0.60P/E (Trailing)‪4,069.60%‬Profit Margin
- BOBOLTCSEBolt Metals Corp.9.28MMarket Cap-53.21%52-week change-0.27P/E (Trailing)‪0.00%‬Profit Margin
- ASEPCSEAsep Medical Holdings Inc.2.06MMarket Cap-284.62%52-week change-0.27P/E (Trailing)‪97.18%‬Profit Margin
- BRAXCSEBraxia Scientific Corp.1.41MMarket Cap+0.00%52-week change-0.08P/E (Trailing)‪9.11%‬Profit Margin
Profile Summary - BIOV - BioVaxys Technology Corp.
About
BioVaxys Technology Corp. is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. It leverages its proprietary DPX™ immune-educating delivery technology platform alongside its Haptenix© neoantigen tumor cell construct platform to create…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
